Androvax, also known as androstenedione:human serum albumin conjugate, is an immunogen and vaccine against androstenedione that is used in veterinary medicine to increase the ovulation rate and number of lambs born to ewes.[1][2][3] It is a conjugate of androstenedione and human serum albumin.[1][3] The drug is marketed in New Zealand.[1][3]
| Combination of | |
|---|---|
| Androstendione | Androstane steroid |
| Human serum albumin | Serum protein |
| Clinical data | |
| Trade names | Androvax |
| Other names | Androstenedione:human serum albumin conjugate |
| AHFS/Drugs.com | Monograph |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Androvax produces immunity against androstenedione, and the generation of antibodies against androstenedione decreases circulating levels of androstenedione.[1] In addition, since androstenedione is the major precursor of estrogens, estrogen levels are decreased as well.[1] This is thought to result in reduced negative feedback on the hypothalamic-pituitary-gonadal axis and increased gonadotropin secretion, which in turn improves fertility and fecundity.[1]
See also
editReferences
edit- ^ a b c d e f Jindal SK, Sharma MC (2010). Biotechnology in Animal Health and Production. New India Publishing. pp. 77–. ISBN 978-93-80235-35-6.
- ^ Reproductive Technologies in Farm Animals. CABI. 2004. pp. 206–. ISBN 978-0-85199-049-1.
- ^ a b c "Androvax Label" (PDF). Schering-Plough Animal Health Ltd. MSD Animal Health.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |